Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00715442 · ClinicalTrials.gov registry record · Phase 2

Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)

A Phase 2 study of Renal Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
50
Enrollment target
2
Study locations

NCT00715442 is a Phase 2 study of Renal Cell Carcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 50 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (79% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00715442, a Phase 2 study of Renal Cell Carcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
2
Study locations

Study Summary

The goal of this clinical research study is to learn if Sutent® (sunitinib malate), given before surgery, can help control renal cell carcinoma. The safety of sunitinib malate will also be studied.

Conditions Studied

Interventions

  • DRUG Sunitinib
  • PROCEDURE Nephrectomy

Study Locations (2)

Texas

  • Baylor College of Medicine - Houston
  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2008-06-24
Est. Completion 2026-12-04
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT00715442

The ClinicalTrials.gov registry entry for NCT00715442 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (79% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Sunitinib is the first listed.

NCT00715442 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00715442 about?

NCT00715442 is a clinical study titled "Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)". The goal of this clinical research study is to learn if Sutent® (sunitinib malate), given before surgery, can help control renal cell carcinoma. The safety of sunitinib malate will also be studied.

What is the current status of trial NCT00715442?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2008-06-24. Estimated completion is 2026-12-04.

What conditions does trial NCT00715442 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma.

What interventions are being tested in trial NCT00715442?

The interventions under investigation include: Sunitinib (DRUG), Nephrectomy (PROCEDURE).

Who is sponsoring clinical trial NCT00715442?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00715442 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.